Last Update 23 Feb 26

Fair value Decreased 30%

XAIR: Later FDA Decision Will Still Support Long Term Upside Potential

Analysts have cut their average price target for Beyond Air from about $12.33 to $8.67, reflecting updated expectations for slower revenue growth, a higher discount rate, and a higher future P/E multiple as they factor in revised sales estimates tied to the later FDA decision timing for the second generation LungFit PH system.

Analyst Commentary

Bullish Takeaways

Bullish analysts still frame the second generation LungFit PH system as a central driver for Beyond Air's long term revenue profile, pointing to commercialization of this product as a potential turning point for the business once regulatory milestones are met.
The view that LungFit PH can support "sustainably high revenue growth and profitability" underpins more constructive stances on the stock's long term earnings power, even with a lower near term price target.
Supportive analysts see the current valuation as reflecting a long wait for the FDA decision. They argue this could leave room for upside if execution on development and commercialization tracks with revised expectations.
Some bullish views lean on the idea that a clearer regulatory timeline, even if extended to the end of 2026, reduces uncertainty around modeling future cash flows and potential P/E multiples tied to LungFit PH.

Bearish Takeaways

Bearish analysts focus on the reduced sales estimates, which are tied directly to the expectation that FDA approval for the second generation LungFit PH system may not arrive until the end of 2026. This extends the period before any meaningful revenue contribution.
The cut in price targets, such as a move from US$6 to US$2, reflects concern that a longer path to commercialization could weigh on valuation metrics, especially if interim revenue sources do not offset the timing shift.
Cautious views highlight execution risk around reaching profitability, since the key product catalyst is now modeled further out and may require additional investment and time before contributing to earnings.
Some bearish analysts worry that the combination of lower near term sales assumptions and a higher discount rate used in models could limit the scope for P/E expansion until there is more concrete visibility on regulatory outcomes.

What's in the News

Beyond Air reaffirmed revenue guidance for the fiscal year ending March 31, 2026, keeping its target range at US$8 million to US$10 million, which gives you a reference point for how management is framing the current commercial outlook for the business (Corporate Guidance).
The company announced a private placement of 3,930,818 common shares (or pre funded warrants) plus associated warrants at a combined purchase price of US$1.272 per share and warrant, for expected gross proceeds of about US$5 million, with the transaction structured under exemptions from registration under the Securities Act (Private Placements).
Beyond Air closed this private placement transaction on January 16, 2026, confirming that the company has recently raised additional capital, with a 7% placement fee and reimbursement of up to US$50,000 in placement agent expenses (Private Placements).
The company appointed Daniel Moorhead as Chief Financial Officer effective January 5, 2026, following the prior resignation of Doug Larson and interim service by controller Denton “Duke” Dewrell. This signals a transition in finance leadership with a new permanent CFO in place (Executive Changes).
Beyond Air reported new international distribution agreements for LungFit PH covering Germany, Brazil, Austria, the Netherlands and Sri Lanka, bringing total international coverage to 39 countries and expanding access to its tankless nitric oxide system that uses ambient air instead of high pressure cylinders (Client Announcements).

Valuation Changes

Fair Value: The consensus fair value estimate moved from $12.33 to $8.67, indicating a lower assessed upside in the updated models.
Discount Rate: The discount rate increased from 9.09% to 12.33%, a sizable step up that makes future cash flows less valuable in present value terms.
Revenue Growth: The revenue growth assumption shifted from a very large triple digit figure to 75.82%, representing a substantial reset in how quickly analysts expect sales to scale.
Net Profit Margin: The net profit margin expectation edged up from 12.88% to 13.33%, indicating slightly higher assumed profitability once the business is scaled.
Future P/E: The future P/E multiple moved from 14.06x to 29.38x, implying a higher valuation multiple applied to projected earnings in the longer term.

6 views

Key Takeaways

International expansion and partnerships are driving greater market access, positioning the company for sustained revenue growth in advanced respiratory care.
Product innovation and operational efficiencies are improving scalability, margin potential, and revenue stability through recurring contracts and long-term customer relationships.
Heavy reliance on a single core platform, ongoing losses, and competitive pressures expose Beyond Air to revenue volatility, margin risks, and potential shareholder dilution.

Catalysts

About Beyond Air

A commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.What are the underlying business or industry changes driving this perspective?

Strong global expansion with distribution partners now covering over 30 countries and access to more than 2 billion people positions Beyond Air to capitalize on the growing demand for advanced respiratory care fueled by aging populations and rising healthcare expenditures, likely driving sustained revenue growth.
Integration into two of the largest U.S. Group Purchasing Organizations (Vizient and Premier) lowers sales cycle friction and improves market access, aligning with the increasing emphasis on non-pharmaceutical interventions in respiratory care and enhancing the company's ability to scale recurring revenues.
Upcoming launch of the second-generation LungFit system, designed for portability and broader hospital use, responds to digital health transformation trends and is expected to significantly boost market share, total nitric oxide volumes, and eventually improve gross and net margins as adoption accelerates.
Substantial operational cost reductions (over 40% YoY decrease in operating expenses and 60% drop in cash burn) have created operating leverage; as new revenues ramp with international and domestic expansion, incremental sales should increasingly flow to earnings.
The transition to multiyear and recurring hospital contracts, together with longer-term customer relationships and expanding use-cases, supports revenue stability and visibility, which is a tailwind for improving margin and earnings quality over time.

Beyond Air Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Beyond Air's revenue will grow by 119.9% annually over the next 3 years.
Analysts assume that profit margins will increase from -880.7% today to 1.2% in 3 years time.
Analysts expect earnings to reach $622.2 thousand (and earnings per share of $0.15) by about September 2028, up from $-42.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.2 million in earnings, and the most bearish expecting $-7.4 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 142.7x on those 2028 earnings, up from -0.3x today. This future PE is greater than the current PE for the US Medical Equipment industry at 28.6x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.74%, as per the Simply Wall St company report.

Beyond Air Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Beyond Air remains heavily reliant on one core platform (LungFit PH and its upcoming Gen II version); delays in FDA approval or underperformance in clinical adoption of the Gen II system could significantly constrain revenue growth, limit margin expansion, and increase earnings volatility.
The company continues to post material net losses (Q1 2026 net loss of $7.7 million), with cash and equivalents of just $6.5 million as of June 30, 2025-raising substantial dilution risk if internal projections are missed or costs rise, thus putting pressure on future per-share earnings and overall shareholder returns.
Entry into large US hospital systems via group purchasing organizations (GPOs) like Premier and Vizient may compress ASPs and extend sales cycles as buyers gain negotiating leverage, posing potential headwinds to sustained top-line growth and long-term gross margins.
International expansion is still in early, unproven stages; sales so far are primarily to distribution partners for demonstration/training, and actual hospital adoption is likely to lag by several quarters, creating long cycles before material recurring revenues may be realized and increasing revenue forecasting risk.
Industry-wide pressures around healthcare cost containment and rising competition from both large device manufacturers and agile startups in respiratory care could threaten Beyond Air's market share, compress pricing power, and undermine net margin improvement over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $11.2 for Beyond Air based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $5.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $50.9 million, earnings will come to $622.2 thousand, and it would be trading on a PE ratio of 142.7x, assuming you use a discount rate of 9.7%.
Given the current share price of $2.31, the analyst price target of $11.2 is 79.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Beyond Air?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

XAIR: Global Network Expansion Will Drive Long-Term Market Presence